Previous 10 | Next 10 |
Shares of PAVmed (NASDAQ:PAVM) are down 10% in after-hours trading after the company's Q3 2021 earnings results missed estimates on revenue, while EPS was in-line. On a non-GAAP basis, the company's net loss widened ~121% to ~$12.3M (-$0.10 per share adjusted). Operating expenses in...
PAVmed (NASDAQ:PAVM): Q3 Non-GAAP EPS of -$0.10 in-line; GAAP EPS of -$0.15 misses by $0.02. Revenue of $0.2M misses by $0.08M. Press Release For further details see: PAVmed EPS in-line, misses on revenue
PAVmed (NASDAQ:PAVM) shares have lost ~6.7% in the post-market after the company disclosed preliminary financial results for the third quarter of 2021 that fell short of Street forecasts. The company has recorded $0.20M in revenue for the quarter, while the consensus revenue es...
Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (...
BEST, DLB, DLO, GSM, DADA, PAVM, SBLK, STNE, TTCF, VREX For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
Patients in Denver, Salt Lake City, and Las Vegas metropolitan areas now have access to a rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) ...
Company conference call and webcast at 4:30PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics ...
Panelists discussed Veris’ vision and strategy to transform cancer care and join the current digital health revolution PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage m...
BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (“Veris”) today announced the appointment of Silicon Valley technology executive ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...